The safety and efficacy of tartillerin in patints with SCD

The safety and efficacy of tartillerin in patints with SCD - The safety and efficacy of tartillerin in patints with SCD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006214

Enrollment

Registered

2011-08-22

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinocerebellar degeneration

Interventions

Oral administration of Tartillerin at dosage of 10mg daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with spinocerebellar degeneration 2)Patients with informed of consent

Exclusion criteria

Exclusion criteria: Patient whom doctor judged to be undesirable as object of examination

Design outcomes

Primary

Measure	Time frame
The improvement of ataxia using SARA score or ICARS. Spiral drawing. Tapping test	—

Countries

Japan

Contacts

Public ContactNAOHISA UEDA

Yokohama City University School of Medicine Neurology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026